In a phase 2 challenge trial in 108 healthy US adults, two-dose live-attenuated WRSs2 vaccine cut adjudicated shigellosis after S sonnei challenge to 9% (3/34) vs 81% (21/26) with placebo (efficacy 89%); six had grade 3 post-vaccination adverse events.
RCTn = 108
Rouphael et al. Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial